Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open label study of radiotherapy concurrent with Apatinib
Mesylate after surgery in patients with advanced head and neck soft tissue and bone sarcomas.
The primary purpose of this study is to evaluate the efficacy and safety of Apatinib Mesylate
in patients with head and neck soft tissue and bone sarcomas.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University